The April issue of Vascular Disease Management is available now. In this issue, editor in chief Frank Criado, MD, FACS, FSVM, discusses surveillance of abdominal aortic aneurysms. In the Case Files by Dr. George column, Dr. George and Dr. Mareddy present a case of acute limb ischemia from septic emboli managed endovascularly. Kfoury et al present application of a modified “trap door” technique for thoracic outlet syndrome. Stauber et al present a case of right brachial stenting in a 79-year-old woman. And Vascular Disease Management interviews Johannes Lammer, MD, about results of the ESPRIT I study for the Esprit bioresorbable vascular scaffold. Access the issue below.
Volume 10 – Issue 4 – April 2013
Editor’s Corner » Abdominal Aortic Aneurysm
Authors of a meta-analysis on small abdominal aortic aneurysms found that aneurysm growth and rupture rates varied considerably across the various studies.
Case Files by Dr. George » Acute Limb Ischemia
The authors present a case of lower extremity acute limb ischemia from septic emboli treated with combined percutaneous rheolytic thrombectomy and balloon angioplasty.
Vascular Technique » Thoracic Outlet Syndrome
Modified “Trap Door” Approach for Thoracic Outlet Syndrome Complicated by Subclavian Artery Aneurysm
The authors present a case of a 46-year-old male with left arterial thoracic outlet syndrome and left subclavian artery aneurysm treated with a modified “trap door” approach.
Case Report » Brachial Artery
A 79-year-old woman with a history of coronary artery disease and hypertension 10 months post 2-vessel coronary artery bypass surgery presented with pain, numbness, and weakness in her right hand that had been increasing in severity for several months. Her right brachial artery was stented, with symptomatic relief and no evidence of restenosis at 1 year.
Interview » Bioresorbable Vascular Scaffold
ESPRIT I Bioresorbable Vascular Scaffold 30-Day Study Results: An Interview with Johannes Lammer, MD
The objective of the ESPRIT I study was to evaluate the safety and performance of the Esprit bioresorbable vascular scaffold in subjects with symptomatic atherosclerotic disease of the SFA or iliac arteries.Vascular Disease Management interviewed Johannes Lammer, MD, principal investigator for the ESPRIT I trial, about the 30-day results of the study.